COVID-19 검사 시장 : 시장 예측(2026-2032년)

The COVID-19 Testing Market is projected to grow by USD 23.15 billion at a CAGR of 2.96% by 2032.

COVID-19 Testing Executive Summary

COVID-19 testing remains a critical component of infectious disease surveillance, clinical triage, outbreak response, and public health preparedness. The testing ecosystem includes molecular diagnostics such as RT-PCR and nucleic acid amplification tests, rapid antigen tests, serology assays, sample collection systems, laboratory information workflows, and increasingly decentralized point-of-care testing models. Demand patterns have evolved from emergency mass-screening programs toward targeted testing for symptomatic individuals, high-risk settings, travel and workplace protocols where applicable, hospital admission screening, variant monitoring, and integrated respiratory testing panels that differentiate SARS-CoV-2 from influenza, RSV, and other respiratory pathogens. Regulatory agencies and public health authorities continue to emphasize test accuracy, turnaround time, accessibility, genomic surveillance integration, and quality management across laboratories and decentralized care environments. As COVID-19 becomes part of ongoing respiratory disease management, industry stakeholders are prioritizing resilient supply chains, automated laboratory operations, digital reporting, multiplex assay development, and equitable access to reliable diagnostics.

Transformative Shifts in the COVID-19 Testing Landscape

The COVID-19 testing landscape has shifted from reactive emergency deployment to a more structured, surveillance-led, and clinically integrated model. During the acute pandemic phase, public health systems expanded high-throughput PCR capacity, emergency-use authorization pathways, drive-through testing, home sample collection, and rapid antigen distribution. The current environment is characterized by selective testing strategies, stronger laboratory preparedness, and broader use of multiplex respiratory diagnostics to support clinical decision-making during seasonal infection surges. A major transformation is the move from standalone SARS-CoV-2 testing toward syndromic panels that can identify multiple respiratory pathogens from a single sample, improving treatment decisions, infection control, and antimicrobial stewardship. Decentralized testing has also matured, with point-of-care and at-home formats playing an important role in rapid risk assessment, although confirmatory laboratory testing remains important in clinical, epidemiological, and high-consequence settings. Meanwhile, genomic sequencing and variant surveillance continue to inform vaccine strain selection, public health guidance, and outbreak risk assessment. The landscape is increasingly shaped by quality assurance, reimbursement policy, data interoperability, and the ability to maintain surge-ready diagnostic capacity without the inefficiencies seen during early pandemic supply shortages.

Cumulative Impact of Artificial Intelligence on COVID-19 Testing

Artificial intelligence is increasingly influencing COVID-19 testing through workflow optimization, assay interpretation support, demand planning, genomic surveillance, and public health analytics. In laboratory environments, AI-enabled systems can help prioritize samples, detect operational bottlenecks, improve instrument utilization, and support quality control by identifying unusual result patterns or potential process deviations. In clinical settings, machine learning models can combine symptoms, exposure history, imaging findings, vaccination status, and laboratory results to support triage and testing decisions, although such tools require careful validation to avoid bias and inappropriate clinical reliance. AI is also valuable in genomic epidemiology, where algorithms assist in identifying emerging variants, tracking mutation patterns, and linking sequencing data with epidemiological signals. For decentralized and at-home testing, AI-supported mobile applications may improve instructions for use, result capture, reporting compliance, and linkage to care. However, the cumulative impact of AI depends on secure data governance, transparent model validation, interoperability with public health systems, and adherence to regulatory expectations for clinical decision support. The strongest near-term value lies in augmenting, not replacing, validated diagnostic workflows, especially where high testing volumes, complex respiratory panels, and rapid reporting requirements create operational pressure.

Key Regional Insights for COVID-19 Testing

Asia-Pacific continues to be central to COVID-19 testing due to its dense urban populations, large diagnostics and consumables manufacturing base, and strong public health surveillance capabilities in countries such as China, India, Japan, South Korea, and Australia. The region has demonstrated extensive use of PCR testing, rapid antigen programs, digital health reporting, and wastewater and genomic surveillance, while current priorities include multiplex respiratory testing, surge readiness, and preparedness for future outbreaks. Europe has a mature diagnostics environment supported by public health coordination, laboratory accreditation, national reference laboratories, and variant monitoring, with increasing attention to integrated respiratory disease surveillance, cross-border health security, and harmonized quality expectations across health systems. North America is characterized by advanced molecular diagnostics infrastructure, broad laboratory networks, regulatory oversight, high adoption of home and point-of-care testing, and ongoing emphasis on respiratory virus differentiation, hospital testing protocols, wastewater monitoring, genomic sequencing, and public health data connectivity. Latin America has strengthened laboratory capacity since the pandemic, with Brazil and Mexico serving as important anchors for diagnostic access, public health testing, and sequencing activity, although geographic disparities, reimbursement constraints, and logistics continue to influence test availability. Africa has expanded molecular testing capacity through pandemic-era investments and regional laboratory networks, but uneven infrastructure, workforce limitations, supply chain dependence, and access gaps remain important considerations; at the same time, strengthened surveillance networks and pathogen genomics initiatives are improving readiness for COVID-19 and other emerging infectious diseases. The Middle East has invested in modern laboratory infrastructure, airport and travel-related screening capabilities during earlier pandemic phases, and health system digitization, while current testing strategies are increasingly aligned with hospital infection control, high-mobility population management, and outbreak preparedness.

Key Group Insights for COVID-19 Testing

NATO countries, while aligned primarily through security cooperation, share strategic concerns related to force readiness, biosecurity, medical logistics, deployed personnel health, and continuity of operations, making reliable COVID-19 testing and broader respiratory pathogen detection relevant for military health systems and critical infrastructure protection. G7 countries typically demonstrate advanced laboratory automation, established regulatory pathways, reimbursement mechanisms, public health sequencing capacity, and high adoption of molecular and multiplex testing, with emphasis on pandemic preparedness, stockpiling strategies, data interoperability, and protection of high-risk populations. BRICS countries collectively represent substantial testing complexity due to large populations, varied healthcare access, domestic diagnostic manufacturing capabilities, and significant roles in global public health surveillance; priorities include affordability, scalability, sequencing capacity, decentralized diagnostics, and resilient supply chains. The European Union benefits from coordinated regulatory frameworks, disease surveillance mechanisms, laboratory networks, and cross-border health security cooperation, enabling stronger alignment in test validation, variant tracking, respiratory infection monitoring, and preparedness planning. ASEAN markets reflect diverse COVID-19 testing maturity, ranging from highly digitized public health systems to settings where decentralized access and laboratory expansion remain priorities; the group's experience with border controls, community testing, and regional manufacturing has increased interest in affordable rapid tests, multiplex respiratory diagnostics, and resilient procurement systems. The GCC has advanced healthcare infrastructure, strong investment capacity, and extensive digital health adoption, supporting sophisticated laboratory testing, point-of-care deployment, rapid public health response capabilities, and testing strategies suited to high-mobility resident, workforce, and travel populations.

Key Country Insights for COVID-19 Testing

China has large-scale testing experience, substantial diagnostics manufacturing capacity, and continued relevance in surveillance, respiratory pathogen monitoring, and supply chain resilience. The United States has one of the most advanced COVID-19 testing ecosystems, supported by large clinical laboratory networks, at-home antigen test adoption, hospital-based molecular testing, public health surveillance, wastewater monitoring, and genomic sequencing capabilities. Japan emphasizes high-quality diagnostics, hospital-centered testing, and surveillance for respiratory infections in an aging population, while India combines large population needs with expanding domestic diagnostics manufacturing, molecular laboratory networks, and growing point-of-care access, though rural reach and affordability remain central concerns. Germany benefits from robust laboratory medicine infrastructure, high-quality molecular diagnostics, and strong clinical laboratory networks, while the United Kingdom has extensive pandemic-era testing experience, strong genomic surveillance expertise, and increasing focus on targeted testing and integrated respiratory monitoring. Australia has strong public health laboratory coordination, border-health experience, and integrated respiratory surveillance, and France maintains established public health and hospital testing systems with emphasis on surveillance, infection control, and diagnostic quality. South Korea is recognized for rapid diagnostic deployment, digital reporting, efficient public health response infrastructure, and continued readiness for COVID-19 and other emerging respiratory pathogens. Italy and Spain, both heavily affected during the early pandemic, strengthened laboratory networks and surveillance approaches and continue to prioritize hospital testing, respiratory disease differentiation, and vulnerable population protection. Canada emphasizes coordinated public health testing, laboratory quality systems, and respiratory virus surveillance, with provincial differences shaping access and prioritization. Russia has significant national laboratory capacity and public health testing infrastructure, with continued focus on domestic diagnostic capability and infectious disease monitoring. Brazil remains a major Latin American testing hub, supported by public health laboratories, academic sequencing programs, and private diagnostics, although regional disparities affect consistency of access. Mexico has expanded diagnostic capacity since the pandemic, with public and private testing channels supporting clinical diagnosis and surveillance, while access varies across regions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient, quality-assured testing platforms that can pivot between routine respiratory diagnostics and surge response. Product strategies should focus on clinically useful multiplex assays, simplified point-of-care workflows, reliable home testing support, and compatibility with digital reporting systems. Laboratories and healthcare providers should invest in automation, workforce training, biosafety, and interoperable information systems to reduce turnaround times and strengthen surveillance reporting. Diagnostic developers should maintain rigorous analytical and clinical validation, especially for emerging variants and multiplex panels, while aligning with evolving regulatory expectations. Public and private stakeholders should diversify suppliers for reagents, swabs, plastics, controls, and instruments to reduce disruption risk. Leaders should also strengthen partnerships with public health agencies, hospitals, pharmacies, and community health organizations to improve access in underserved populations. Ethical AI adoption, cybersecurity, patient privacy, and transparent data governance should be embedded into digital testing workflows. Above all, organizations should treat COVID-19 testing as part of a broader respiratory disease preparedness strategy rather than a standalone pandemic-era product category.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, scientific, and industry-relevant sources. The methodology emphasizes evidence from national and regional public health agencies, international health organizations, peer-reviewed medical literature, regulatory guidance, laboratory medicine standards, clinical diagnostic practice updates, and documented trends in testing deployment, surveillance, and technology adoption. Insights are synthesized by examining test modality evolution, regulatory changes, clinical utility, laboratory operations, regional health system capabilities, genomic surveillance activities, supply chain resilience, wastewater monitoring, point-of-care deployment, and digital health integration. The analysis avoids unverified projections and does not rely on market sizing, market share, or forecasting. Regional, group, and country insights are assessed through publicly observable healthcare infrastructure, testing policy evolution, diagnostic access, public health surveillance capacity, regulatory maturity, and pandemic preparedness indicators. The research process applies cross-validation across multiple credible sources to ensure consistency, relevance, and data-backed interpretation for strategic decision-making in COVID-19 testing.

Conclusion

COVID-19 testing has evolved from emergency mass screening into a durable pillar of respiratory disease management, outbreak preparedness, and public health surveillance. The sector's long-term relevance is supported by continued SARS-CoV-2 circulation, the need to protect high-risk populations, the clinical value of distinguishing COVID-19 from influenza and RSV, and the importance of variant monitoring. The most significant opportunities are linked to multiplex testing, decentralized access, laboratory automation, genomic surveillance, AI-enabled workflow support, and interoperable digital reporting. At the same time, stakeholders must address affordability, quality assurance, regulatory compliance, equitable access, and supply chain resilience. Organizations that integrate COVID-19 diagnostics into broader infectious disease strategies will be better positioned to support healthcare systems during seasonal surges, localized outbreaks, and future public health emergencies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. COVID-19 Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Molecular Tests
  • 7.2.1. Single Target RT-PCR
  • 7.2.2. Multiplex RT-PCR
  • 7.2.3. Isothermal Amplification Tests
• 7.3. Antigen Tests
  • 7.3.1. Laboratory Antigen Tests
  • 7.3.2. At Home Antigen Tests
• 7.4. Serology Tests

8. COVID-19 Testing Market, by Sample Type

• 8.1. Introduction
• 8.2. Upper Respiratory Samples
  • 8.2.1. Nasopharyngeal Swab
  • 8.2.2. Oropharyngeal Swab
  • 8.2.3. Anterior Nasal Swab
• 8.3. Lower Respiratory Samples
  • 8.3.1. Sputum
  • 8.3.2. Bronchoalveolar Lavage
  • 8.3.3. Tracheal Aspirate
• 8.4. Saliva Samples
• 8.5. Blood And Plasma Samples

9. COVID-19 Testing Market, by Product Type

• 9.1. Introduction
• 9.2. Test Kits And Reagents
  • 9.2.1. Molecular Test Kits
  • 9.2.2. Antigen Test Kits
  • 9.2.3. Serology Test Kits
  • 9.2.4. Controls And Calibrators
  • 9.2.5. Sample Preparation Reagents
• 9.3. Services
  • 9.3.1. Laboratory Testing Services
  • 9.3.2. Outsourced Testing Services
  • 9.3.3. Data Analytics And Reporting Services

10. COVID-19 Testing Market, by End User

• 10.1. Introduction
• 10.2. Hospitals And Clinics
  • 10.2.1. Acute Care Hospitals
  • 10.2.2. Specialty Hospitals
  • 10.2.3. Outpatient Clinics
• 10.3. Diagnostic Laboratories
  • 10.3.1. Independent Reference Laboratories
  • 10.3.2. Hospital Affiliated Laboratories
• 10.4. Physician Offices
• 10.5. Academic And Research Institutes

11. COVID-19 Testing Market, by Region

• 11.1. Asia-Pacific
• 11.2. Europe
• 11.3. North America
• 11.4. Latin America
• 11.5. Africa
• 11.6. Middle East

12. COVID-19 Testing Market, by Group

• 12.1. NATO
• 12.2. G7
• 12.3. BRICS
• 12.4. European Union
• 12.5. ASEAN
• 12.6. GCC

13. COVID-19 Testing Market, by Country

• 13.1. China
• 13.2. United States
• 13.3. Japan
• 13.4. India
• 13.5. Germany
• 13.6. United Kingdom
• 13.7. Australia
• 13.8. France
• 13.9. South Korea
• 13.10. Italy
• 13.11. Canada
• 13.12. Russia
• 13.13. Brazil
• 13.14. Mexico
• 13.15. Spain

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 1DROP Diagnostics
• 15.2. Abbott Laboratories
• 15.3. ADT Biotech Sdn Bhd
• 15.4. Aldatu Biosciences
• 15.5. altona Diagnostics GmbH
• 15.6. Avellino Lab USA, Inc.
• 15.7. bioMerieux SA
• 15.8. Co-Diagnostics, Inc.
• 15.9. Curetis GmbH
• 15.10. Danaher Corporations
• 15.11. F. Hoffmann-La Roche AG
• 15.12. GenMark Diagnostics, Inc.
• 15.13. Hologic, Inc.
• 15.14. Laboratory Corporation of America Holdings
• 15.15. Luminex Corporation
• 15.16. Mylab Discovery Solutions Pvt. Ltd.
• 15.17. Perkin Elmer, Inc.
• 15.18. Quidel Corporation
• 15.19. Randox Laboratories Ltd.
• 15.20. SD Biosensor, Inc.
• 15.21. Seegene, Inc.
• 15.22. Shenzhen Bioeasy Biotechnology Co., Ltd.
• 15.23. Siemens Healthineers AG
• 15.24. SolGent Co.,Ltd.
• 15.25. Thermo Fisher Scientific Inc.